SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics® Presents Real-World Pathlight™ MRD Data at ASCO GI 2026
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
Prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy
Neo-N: three-year event-free survival (EFS) and overall survival (OS) and ultrasensitive ctDNA and tumor infiltrating lymphocyte (TIL) dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab
CATER-MRD: Capecitabine for Targeted Eradication of aRising ctDNA Molecular Residual Disease in ER+/HER2-negative Breast Cancer
CLAIRE: A Multicenter, Prospective Single-arm Phase II Study Evaluating Liquid Biopsy Guided Intensified Follow-up Surveillance in Patients with Intermediate to High-risk ER+/HER2-negative Early-stage Breast Cancer
Longitudinal ctDNA Tracking in Early and Recurrent Breast Cancer Using an Ultrasensitive Structural Variant-Based Assay: An Updated Analysis from the TRACER Study
SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics Showcases New Pathlight MRD Data at SABCS 2025
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics® to Present at the Jefferies Global Healthcare Conference in London 2025
We are pleased to announce that SAGA will be presenting at the Jefferies Global Healthcare Conference in London—celebrating the 16th anniversary of Europe’s largest healthcare-dedicated investor event.